Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash from Operations (2019 - 2023)

Historic Cash from Operations for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to -$31.6 million.

  • ADC Therapeutics' Cash from Operations rose 7711.51% to -$31.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$118.7 million, marking a year-over-year increase of 1418.9%. This contributed to the annual value of -$123.8 million for FY2024, which is 433.83% down from last year.
  • Per ADC Therapeutics' latest filing, its Cash from Operations stood at -$31.6 million for Q4 2023, which was up 7711.51% from -$36.7 million recorded in Q3 2023.
  • ADC Therapeutics' 5-year Cash from Operations high stood at $2195.0 for Q3 2022, and its period low was -$138.2 million during Q4 2022.
  • Over the past 5 years, ADC Therapeutics' median Cash from Operations value was -$58588.0 (recorded in 2021), while the average stood at -$19.3 million.
  • Per our database at Business Quant, ADC Therapeutics' Cash from Operations skyrocketed by 10374.65% in 2022 and then plummeted by 167085170.84% in 2023.
  • Quarter analysis of 5 years shows ADC Therapeutics' Cash from Operations stood at -$33655.0 in 2019, then tumbled by 95285.53% to -$32.1 million in 2020, then skyrocketed by 99.81% to -$61631.0 in 2021, then plummeted by 224180.48% to -$138.2 million in 2022, then surged by 77.12% to -$31.6 million in 2023.
  • Its Cash from Operations stands at -$31.6 million for Q4 2023, versus -$36.7 million for Q3 2023 and -$35.0 million for Q2 2023.